Rasmus Rabøl

Rasmus Rabøl is currently the corporate vice president of translational science and medicine at Novo Nordisk. Rasmus was previously a postdoctoral fellow at Yale University School of Medicine, where they conducted in vivo human studies on muscular insulin resistance and lipid metabolism in young insulin resistant subjects, as well as rodent studies on the effects of gastric bypass on glucose metabolism. Prior to that, they were a medical advisor at the Danish Medicines Agency, responsible for assessment of risk management plans as rapporteur or co-rapporteur. Rasmus Rabøl also has a PhD from the University of Copenhagen, where their thesis was on muscular insulin resistance and mitochondrial function based on interventional studies in patients with type 2 diabetes. Rasmus has also completed fellowships in endocrinology at Hvidovre University Hospital and in internal medicine at Region Zealand.

Rasmus Rabøl completed a Doctor of Medicine (MD) at Københavns Universitet - University of Copenhagen in the field of medicine. Rasmus then pursued a Master's degree in Pharmaceutical Medicine at the University of Surrey. Currently, Rasmus Rabøl is completing their Doctor of Philosophy (PhD) in Type 2 Diabetes and Skeletal Muscle Insulin Resistance at Københavns Universitet - University of Copenhagen.

They work with Lars Fogh Iversen - Senior Vice President, Global Research Technologies, Karin Conde-Knape - Senior Vice President, Global Drug Discovery, and Jacob Sten Petersen - Corporate Vice President, Stem Cell R&D. Rasmus Rabøl reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer.